In a recent Phase 3 study evaluating the safety of nivolumab and ipilimumab for melanoma, monotherapy-related hepatitis was identified in 4% of patients, with severe hepatitis (5–20 × ULN transaminases) in 1% and in 2% of patients treated with nivolumab and ipilimumab, respectively; ALT elevations were reported in 19% of patients treated with combination therapy [31]. The gene discussed is GPT; the disease is Hepatitis.